Literature DB >> 28314175

Choosing wisely - Preclinical test models in the era of precision medicine.

Konrad Klinghammer1, Wolfgang Walther2, Jens Hoffmann3.   

Abstract

Through the introduction of a steadily growing variety of preclinical test models drug development and biomarker research has advanced. Next to classical used 2D cell line cultures, tissue-slice cultures, 3D organoid cell cultures, genetically engineered mouse models, cell line derived mouse models and patient derived xenografts may be selected for a specific question. All models harbor advantages and disadvantages. This review focuses on the available preclinical test models, novel developments such as humanized mice and discusses for which question a particular model should be employed.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CDX; GEMMs; PDX; Preclinical models; Tissue-slice cultures

Mesh:

Substances:

Year:  2017        PMID: 28314175     DOI: 10.1016/j.ctrv.2017.02.009

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  20 in total

1.  Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.

Authors:  Prabhu Ramamoorthy; Sufi Mary Thomas; Gaurav Kaushik; Dharmalingam Subramaniam; Katherine M Chastain; Animesh Dhar; Ossama Tawfik; Anup Kasi; Weijing Sun; Satish Ramalingam; Sumedha Gunewardena; Shahid Umar; Joshua M Mammen; Subhash B Padhye; Scott J Weir; Roy A Jensen; G Sitta Sittampalam; Shrikant Anant
Journal:  Cancer Res       Date:  2019-01-23       Impact factor: 12.701

Review 2.  Monitoring and modulation of the tumor microenvironment for enhanced cancer modeling.

Authors:  Tristen Head; Nathaniel C Cady
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-28

Review 3.  Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.

Authors:  Lukas M Carter; Sophie Poty; Sai Kiran Sharma; Jason S Lewis
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-30       Impact factor: 1.921

Review 4.  Tissue regulatory T cells: regulatory chameleons.

Authors:  Andrés R Muñoz-Rojas; Diane Mathis
Journal:  Nat Rev Immunol       Date:  2021-03-26       Impact factor: 53.106

Review 5.  Modeling phenotypes of malignant gliomas.

Authors:  Oltea Sampetrean; Hideyuki Saya
Journal:  Cancer Sci       Date:  2017-11-15       Impact factor: 6.716

6.  Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity.

Authors:  Bruna R S Correa; Joanna Hu; Luiz O F Penalva; Richard Schlegel; David L Rimm; Pedro A F Galante; Seema Agarwal
Journal:  Sci Rep       Date:  2018-03-06       Impact factor: 4.379

7.  3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis.

Authors:  Tijmen H Booij; Leo S Price; Erik H J Danen
Journal:  SLAS Discov       Date:  2019-02-28       Impact factor: 3.341

Review 8.  Engineering Breast Cancer On-chip-Moving Toward Subtype Specific Models.

Authors:  Carmen Moccia; Kristina Haase
Journal:  Front Bioeng Biotechnol       Date:  2021-06-23

9.  Comparing the genomes of cutaneous melanoma tumors to commercially available cell lines.

Authors:  Stephen A Luebker; Weiwei Zhang; Scott A Koepsell
Journal:  Oncotarget       Date:  2017-12-04

10.  Editorial: Cancer Models.

Authors:  Michael Breitenbach; Jens Hoffmann
Journal:  Front Oncol       Date:  2018-10-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.